Embecta Corp. (EMBC) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Embecta Corp. · Health Care · ref. ETF XLV · 24 calls · price $6.2
What the company does: Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
📈 Embecta Corp. (EMBC) stock price
$6.2-54.2% over range
Oct 14, 25low $2.9 · high $14.64Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 3 analysts
📊 JPI status : Embecta Corp. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 EMBC price target & analyst consensus — price $6.20
The price target · all analysts combined (2 targets)
Highest target · 1 firm of 2$5-19.4%
Median target · of 2 targets$4-35.5%
Lowest target · 1 firm of 2$3-51.6%
Current price$6.2
⭐ What the most reliable analysts say
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy00%
Hold267%
Sell133%
Strong Sell00%
Go deeper on the analysts
🎯 EMBC price target all
All 24 calls, one by one, with our verdict on each firm.
→ See all 24 targets, analyst by analyst💡 The best analysts on EMBC most reliable
Their real reliability on EMBC, firm by firm: who was right, who was wrong.
→ See their reliability on EMBCAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Embecta Corp.? The JPI assistant answers using our backtest data.
🏛️ Embecta Corp. insider buying: who's buying and how much › open the full page
4 insiders bought4 buys / 6 mo $558k👥 Cluster buy
🔎 Detailed analyses
✅ Historical analyst reliability on EMBC
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Morgan Stanley ↗ | 100% | +24.0% | 8 |
| BTIG ↗ | 0% | -50.5% | 2 |
📊 What $1,000 invested in Embecta Corp. would be worth › open the full page
In short — $1,000 invested in Embecta Corp. 10 years ago would be worth $72.08 today, i.e. -48%/yr on average. Best year: 2024 (+8%), worst: 2025 (-43%). Price performance, excluding dividends.
If I'd invested $1,000 in Embecta Corp.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $151 | -85% |
| 3 years ago | $123 | -88% |
Return by year (Embecta Corp.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -73% | $266 (-73%) |
| 2025 | -43% | $151 (-85%) |
| 2024 | +8% | $164 (-84%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Embecta Corp.
Loading news…
📋 All analyst calls on EMBC
Filtered on — · ✕ show all
B of A Securities ↗
May 18, 26
▼ Underperform · 🎯$3
Price at call : $2.9 — upside +3%
Today : $6.2 — upside -52%
🎯 on EMBC : 100% (1 call matured) · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : May 18, 27
matures : May 18, 27
■ Neutral neutral · not a buy · 🎯$5
Price at call : $3.56 — gap to target +40%
Today : $6.2 — gap to target -19%
🎯 on EMBC : no call matured yet · 📊 on Health : 27.3% · -9.0% (88 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
■ Neutral neutral · not a buy
🎯 on EMBC : 0% (2 calls matureds) · 📊 on Health : 47.1% · +20.0% (68 calls)
in progress (365j)
matures : May 6, 27
matures : May 6, 27
■ Neutral neutral · not a buy · 🎯$12
Price at call : $9.46 — gap to target +27%
Today : $6.2 — gap to target +94%
🎯 on EMBC : no call matured yet · 📊 on Health : 27.3% · -9.0% (88 calls)
in progress (365j)
matures : Apr 13, 27
matures : Apr 13, 27
▲ Buy · 🎯$25
Price at call : $10.86 — upside +130%
Today : $6.2 — upside +303%
🎯 on EMBC : 0% (2 calls matureds) · 📊 on Health : 47.1% · +20.0% (68 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
▲ Buy · 🎯$25
Price at call : $14.96 — upside +67%
Today : $6.2 — upside +303%
Expected +67% · Actual -63% · Reason (≥ +15%) : ✗ No
🎯 on EMBC : 0% (2 calls matureds) · 📊 on Health : 47.1% · +20.0% (68 calls)
-62.9%
stock -63% · XLV +21%
matured Sep 5, 26
■ Neutral neutral · not a buy · 🎯$12
Price at call : $9.75 — gap to target +23%
Today : $6.2 — gap to target +94%
🎯 on EMBC : no call matured yet · 📊 on Health : 27.3% · -9.0% (88 calls)
in progress (365j)
matures : Jul 16, 26
matures : Jul 16, 26
■ Neutral neutral · not a buy · 🎯$13
Price at call : $11.26 — gap to target +15%
Today : $6.2 — gap to target +110%
🎯 on EMBC : no call matured yet · 📊 on Health : 27.3% · -9.0% (88 calls)
in progress (365j)
matures : May 23, 26
matures : May 23, 26
See the other 16 calls, newest to oldest
■ Neutral neutral · not a buy · 🎯$15
Price at call : $12.01 — gap to target +25%
Today : $6.2 — gap to target +142%
🎯 on EMBC : no call matured yet · 📊 on Health : 27.3% · -9.0% (88 calls)
in progress (365j)
matures : Apr 10, 26
matures : Apr 10, 26
▲ Buy · 🎯$26
Price at call : $20.59 — upside +26%
Today : $6.2 — upside +319%
Expected +26% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on EMBC : 0% (2 calls matureds) · 📊 on Health : 47.1% · +20.0% (68 calls)
-38.0%
stock -38% · XLV +7%
matured Nov 27, 25
Morgan Stanley ↗
Jul 15, 24
▼ Underweight · 🎯$12
Price at call : $13.2 — upside -9%
Today : $6.2 — upside +94%
Expected -9% · Actual -26% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+26.1%
stock -26% · XLV -10%
matured Jul 15, 25
Morgan Stanley ↗
May 10, 24
▼ Underweight · 🎯$13
Price at call : $14.18 — upside -8%
Today : $6.2 — upside +110%
Expected -8% · Actual -12% · Reason (≤ −15%) : ✗ No
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+12.5%
stock -12% · XLV -5%
matured May 10, 25
Morgan Stanley ↗
Nov 22, 23
▼ Underweight · 🎯$16
Price at call : $17.62 — upside -9%
Today : $6.2 — upside +158%
Expected -9% · Actual -21% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+20.5%
stock -21% · XLV +10%
matured Nov 21, 24
Morgan Stanley ↗
Oct 18, 23
▼ Underweight · 🎯$15
Price at call : $15.32 — upside -2%
Today : $6.2 — upside +142%
Expected -2% · Actual -11% · Reason (≤ −15%) : ✗ No
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+11.0%
stock -11% · XLV +19%
matured Oct 17, 24
Morgan Stanley ↗
Aug 24, 23
▼ Underweight · 🎯$16
Price at call : $16.94 — upside -6%
Today : $6.2 — upside +158%
Expected -6% · Actual -17% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+17.4%
stock -17% · XLV +17%
matured Aug 23, 24
Morgan Stanley ↗
Jul 18, 23
▼ Underweight · 🎯$19
Price at call : $19.75 — upside -4%
Today : $6.2 — upside +206%
Expected -4% · Actual -32% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+32.4%
stock -32% · XLV +11%
matured Jul 17, 24
Morgan Stanley ↗
May 15, 23
▼ Underweight · 🎯$29
Price at call : $28.71 — upside +1%
Today : $6.2 — upside +368%
Expected +1% · Actual -49% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+49.1%
stock -49% · XLV +9%
matured May 14, 24
Morgan Stanley ↗
Jan 6, 23
▼ Underweight · 🎯$28
Price at call : $25.05 — upside +12%
Today : $6.2 — upside +352%
Expected +12% · Actual -23% · Reason (≤ −15%) : ✓ Yes
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+22.8%
stock -23% · XLV +3%
matured Jan 6, 24
Morgan Stanley ↗
Dec 21, 22
■ Equal-Weight neutral · not a buy · 🎯$31
Price at call : $28.05 — gap to target +11%
Today : $6.2 — gap to target +400%
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Dec 21, 23
matures : Dec 21, 23
Morgan Stanley ↗
Oct 11, 22
■ Equal-Weight neutral · not a buy · 🎯$33
Price at call : $28.09 — gap to target +17%
Today : $6.2 — gap to target +432%
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Oct 11, 23
matures : Oct 11, 23
■ Neutral neutral · not a buy
🎯 on EMBC : 0% (2 calls matureds) · 📊 on Health : 47.1% · +20.0% (68 calls)
in progress (365j)
matures : Sep 8, 23
matures : Sep 8, 23
Morgan Stanley ↗
Aug 16, 22
■ Equal-Weight neutral · not a buy · 🎯$36
Price at call : $32.33 — gap to target +11%
Today : $6.2 — gap to target +481%
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 16, 23
matures : Aug 16, 23
Morgan Stanley ↗
Aug 1, 22
■ Equal-Weight neutral · not a buy · 🎯$33
Price at call : $29.52 — gap to target +12%
Today : $6.2 — gap to target +432%
🎯 on EMBC : 100% (8 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 1, 23
matures : Aug 1, 23
B of A Securities ↗
Jun 21, 22
▼ Underperform · 🎯$25
Price at call : $28.39 — upside -12%
Today : $6.2 — upside +303%
Expected -12% · Actual -13% · Reason (≤ −15%) : ✗ No
🎯 on EMBC : 100% (1 call matured) · 📊 on Health : 51.9% · +3.9% (156 calls)
+12.8%
stock -13% · XLV +7%
matured Jun 21, 23
Frequently asked questions
Should I buy Embecta Corp. stock?
This isn't buy advice. For Embecta Corp., the analyst consensus is "Hold", with an average price target of $4.00 (-35% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (8 calls tracked on Embecta Corp.). We show the numbers — you decide.
Is it too late to buy Embecta Corp.? How high can it go?
The most bullish analyst target on Embecta Corp. is $5.00 (-19% above today's price); the average is $4.00. That's the upside they see. Check how reliable those analysts have actually been on Embecta Corp. on our site before trusting it.
Is Embecta Corp. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 2 analysts have a real record on Embecta Corp., the best hitting 100% over 8 calls. Current consensus: "Hold". Make your call on data, not noise.
Will Embecta Corp. stock recover (go back up)?
It's down from its high. We answer with the numbers — the analysts' 12-month target and what happened after its past drops: will EMBC stock recover (go back up)?
What has Embecta Corp.'s past performance been?
Historical returns and a "how much if I had invested" calculator: EMBC performance & returns.
Are insiders buying EMBC stock?
Executives' and large holders' buys and sells, decoded: insider buying on EMBC.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX